Candida spp. peritonitis (clinical cases, register analysis and literature review)

• Published in: Klinicheskai︠a︡ mikrobiologii︠a︡ i antimikrobnai︠a︡ khimioterapii︠a Vol. 25; no. 3; pp. 311 - 320
• Main Authors: Kozlova, O.P., Khostelidi, Sofya N., Smirnov, S.A., Saturnov, A.V., Mashkevich, I.R., Rysev, A.V., Pichugina, G.A., Bogomolova, T.S., Vybornova, I.V., Vasilieva, N.V., Lobzin, Yuriy V., Klimko, Nikolay N.
• Format: Journal Article
• Language: Russian
• Published: Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy 2023
• Subjects: antimycotic therapy; candida albicans; candida spp; candidiasis; echinocandins; invasive candidiasis; mycotic peritonitis; peritonitis
• ISSN: 1684-4386; 2686-9586
• DOI: 10.36488/cmac.2023.3.311-320

We present a case of fungal peritonitis in a patient secondary to intestinal perforation and repeated laparotomy. An analysis of data from the register of patients with invasive candidiasis is also presented. In the study were included 42 patients with candida peritonitis. The risk factors: antibiotics (100%), vascular catheters (95%), total parenteral nutrition (81%), repeated abdominal surgery (69%), sepsis (69%), bacteremia (50%), repeated perforations on the gastrointestinal tract (43%), oncopathology of the gastrointestinal tract (36%), infected pancreatic necrosis (26%). The etiology agents were C. albicans (50%), C. glabrata (14%), C. parapsilosis (7%). 45% of patients received prophylactic treatment (100% fluconazole). Empirical therapy was carried out by 52% of patients (triazoles – 38%, echinocandins – 14%). After receiving the results of the microbiological study, 3% of patients began to receive antifungal therapy (echinocandins). The 30 days overall survival rate was 66%.